Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...